


PHARMACEUTICAL 2017



UNITED THERAPEUTICS Corp Rank 4 of 313





RealRate

PHARMACEUTICAL 2017



UNITED THERAPEUTICS Corp Rank 4 of 313

The relative strengths and weaknesses of UNITED THERAPEUTICS Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of UNITED THERAPEUTICS Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 596% points. The greatest weakness of UNITED THERAPEUTICS Corp is the variable Other Expenses, reducing the Economic Capital Ratio by 46% points.

The company's Economic Capital Ratio, given in the ranking table, is 355%, being 772% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	1,424,800
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	332,500
Liabilities, Non-Current	130,900
Other Assets	411,500
Other Compr. Net Income	3,600
Other Expenses	419,200
Other Liabilities	0
Other Net Income	-1,500
Property and Equipment	489,300
Research and Development	147,600
Revenues	1,598,800
Selling, General and Administrative Expense	316,800

Output Variable	Value in 1000 USD
Assets	2,325,600
Liabilities	463,400
Expenses	883,600
Stockholders Equity	1,862,200
Net Income	713,700
Comprehensive Net Income	715,500
Economic Capital Ratio	355%

